Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years

Article

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
August's FDA Focus: Approvals and pipeline updates in pediatrics | Image credit: Contemporary Pediatrics
Tina Tan, MD, reacts to state of Florida seeking elimination of all vaccine requirements
© 2025 MJH Life Sciences

All rights reserved.